Severe Psoriasis Market Expected to Show Robust Growth Through 2032, Driven by Novel Biologics and Oral Therapeutics

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
Africa Rallies for Gas-Driven Growth at Invest in African Energy (IAE)...
Gas Exporting Countries Forum (GECF) Secretary General to Highlight...
airBaltic Provides Essential Guidance for a Seamless...
Getting kids back in...
Addressing New Zealand's infrastructure asset management...
'Stop the 21st century atrocity' in Gaza, Fletcher urges UN Security...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

Severe Psoriasis Market Expected to Show Robust Growth Through 2032, Driven by Novel Biologics and Oral Therapeutics | DelveInsight

The severe psoriasis market is experiencing significant expansion with next-generation IL-1 inhibitors, TYK2 blockers, and novel topical formulations addressing the unmet treatment needs. Key psoriasis companies include Johnson & Johnson, Pfizer, LEO Pharma, Novartis, Biocon Biologics, AbbVie,...

If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search